Stralem & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Stralem & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$3.95M	Sell	35,225 -410	-1%	-$43.5K	2.52%	26
2020 Q1	$3.2M	Buy	35,635 +1,200	+3%	+$118K	2.38%	27
2019 Q4	$3.72M	Sell	34,435 -1,460	-4%	-$156K	2.08%	35
2019 Q3	$3.52M	Sell	35,895 -260	-0.7%	-$29.3K	2.03%	32
2019 Q2	$4.74M	Sell	36,155 -7,810	-18%	-$1.01M	2.58%	27
2019 Q1	$5.94M	Sell	43,965 -3,655	-8%	-$454K	2.72%	26
2018 Q4	$4.64M	Sell	47,620 -20,015	-30%	-$2.37M	2.21%	29
2018 Q3	$9.4M	Sell	67,635 -13,900	-17%	-$1.74M	2.79%	23
2018 Q2	$10.1M	Sell	81,535 -35,550	-30%	-$4.15M	2.99%	18
2018 Q1	$13.1M	Buy	+117,085	New	+$14M	2.59%	26

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stralem & Co's ALXN Position: Q2 2020 in Review

Stralem & Co reduced its Alexion Pharmaceuticals (ALXN) stake by 1.2% in Q2 2020, selling an estimated $43.5K and leaving 35,225 shares worth $3.95M. The position accounts for 2.52% of the portfolio, ranked #26.

Stralem & Co first reported a position in ALXN in Q1 2018 and has held it in 10 quarters since. The position peaked at $13.1M in Q1 2018. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Stralem & Co held 35,225 shares of Alexion Pharmaceuticals worth $3.95M as of Q2 2020.
Stralem & Co sold 410 Alexion Pharmaceuticals shares in Q2 2020, an estimated $43.5K.
Alexion Pharmaceuticals made up 2.52% of Stralem & Co's portfolio in Q2 2020, its #26 holding.
Stralem & Co first reported a position in Alexion Pharmaceuticals in Q1 2018 and has held it in 10 quarters since.
Stralem & Co's Alexion Pharmaceuticals position peaked at $13.1M in Q1 2018.
706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.